Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-1,992
Closed -$267K – 205
2021
Q4
$267K Sell
1,992
-420
-17% -$60.4K 0.03% 215
2021
Q3
$330K Sell
2,412
-40
-2% -$5.04K 0.03% 199
2021
Q2
$262K Sell
2,452
-644
-21% -$61.8K 0.03% 220
2021
Q1
$278K Hold
3,096
– – 0.04% 203
2020
Q4
$286K Hold
3,096
– – 0.04% 174
2020
Q3
$319K Sell
3,096
-440
-12% -$46K 0.01% 142
2020
Q2
$358K Sell
3,536
-320
-8% -$28.6K 0.08% 136
2020
Q1
$260K Sell
3,856
-2,464
-39% -$153K 0.08% 142
2019
Q4
$346K Hold
6,320
– – 0.08% 132
2019
Q3
$235K Sell
6,320
-260
-4% -$10.1K 0.06% 147
2019
Q2
$246K Buy
+6,580
New +$207K 0.06% 148

Other funds holding DXCM

Bank Hapoalim BM's DXCM Position: Q1 2022 in Review

Bank Hapoalim BM sold out of DexCom (DXCM) in Q1 2022, closing a stake of 1,992 shares — an estimated $267K sold.

Bank Hapoalim BM first reported a position in DXCM in Q2 2019 and held it in 11 quarters. The position peaked at $358K in Q2 2020. 862 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

  • Bank Hapoalim BM reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
  • Bank Hapoalim BM sold 1,992 DexCom shares in Q1 2022, an estimated $267K.
  • Bank Hapoalim BM first reported a position in DexCom in Q2 2019 and held it in 11 quarters.
  • Bank Hapoalim BM's DexCom position peaked at $358K in Q2 2020.
  • 862 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Bank Hapoalim BM's 13F filing for Q1 2022, filed 28 Apr 2022.